Format

Send to

Choose Destination
Transplantation. 2018 Aug;102(8):1223-1229. doi: 10.1097/TP.0000000000002217.

Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells.

Author information

1
Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI.
2
Department of Surgery, Massachusetts General Hospital, Boston, MA.
3
Harvard Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Boston MA.
4
Juvenile Diabetes Research Foundation, New York, NY.
5
Joslin Diabetes Center, Harvard Medical School, Boston, MA.
6
Department of Physiology, University of Toronto, University of Toronto, Toronto Canada.
7
ViaCyte, Inc., San Diego, CA.
8
Department of Surgery, University of Illinois at Chicago, Chicago, IL.
9
Center for Beta Cell Therapy in Diabetes, Vrije Universiteit Brussel, Brussels, Belgium.
10
eGenesis, Inc., Cambridge MA.
11
Harvard Stem Cell Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
12
Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
13
Columbia Stem Cell Initiative, Columbia University, New York, NY.
14
Broad Institute of MIT and Harvard, Cancer Program, Golub Lab, Cambridge MA.
15
Department of Surgery, University of Cambridge, Cambridge, United Kingdom.
16
Department of Medicine, University of Sydney, Sydney, Australia.
17
Department of Surgery, UCSF Medical Center, San Francisco, CA.
18
National Diabetes Center of Excellence, Leiden University Medical Center, Leiden, The Netherlands.
19
Department of Surgery, University of Miami, Miami, FL.
20
Department of Surgery, University of Pennsylvania, Philadelphia, PA.
21
Center on Diabetes, Obesity, and Metabolism, Wake Forest School of Medicine, Winston-Salem, NC.
22
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA.
23
Department of Medicine, Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
24
Department of Endocrinology and Diabetes, University Hospital Dresden, Dresden, Germany.
25
Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA.
26
Department of Surgery, University of Minnesota, Minneapolis, MN.
27
Carpenter Group Consulting, Seattle, WA.
28
European Infrastructure for Translational Medicine, Amsterdam Netherlands.
29
Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan Italy.
30
Department of Surgery, Geneva University, Geneva, Switzerland.
31
Department of Medicine, St. Vincent's Institute, Melbourne, Australia.

Abstract

Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

PMID:
29781950
DOI:
10.1097/TP.0000000000002217
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center